HaiderSMahdiMDMPH

PubMed

• An LC-MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma.
  Ye Feng, Richard Piekarz, Jan H Beumer, Timothy W Synold, Haider Mahdi> ;Bioanalysis. 2024 Mar 18
• Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignancies.
  Aggarwal, A., Khalighi, S., Babu, D., Li, H., Azarianpour-Esfahani, S., Corredor, G., Fu, P., Mokhtari, M., Pathak, T., Thayer, E., Modesitt, S., Madabhushi, A., Mahdi...> ;Communications Medicine. 2024 Jan 3
• Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer.
  Simpson, P., Zhang, L., Christian, Q., Uyar, D., Michener, C., Bishop, E., Hopp, E., Rader, J., Rose, P., Mahdi, H., Debernardo, R., Bradley, W.> ;Frontiers in Oncology. 2024 Jan 1
• 1 citations
  The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
  Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay, Regina Graul, Amreen Husain, Mansoor Raza Mirza, Brian Slomovitz> ;International Journal of Gynecological Cancer. 2023 Dec 4
• 1 citations
  Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
  Haider Mahdi, Isabelle Ray-Coquard, Domenica Lorusso, Mansoor Raza Mirza, Bradley J Monk, Brian Slomovitz> ;International Journal of Gynecological Cancer. 2023 Nov 6
• 2 citations
  Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.
  Hussein Al-Sudani, Ying Ni, Philip Jones, Huseyin Karakilic, Lei Cui, Lisa D S Johnson, Peter G Rose, Alexander Olawaiye, Robert P Edwards, Robert A Uger, Gloria H Y L...> ;NPJ Precision Oncology. 2023 Jul 19
• 5 citations
  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
  Mary L Disis, Sarah F Adams, Jyoti Bajpai, Marcus O Butler, Tyler Curiel, Shelley A Dodt, Laura Doherty, Leisha A Emens, Claire F Friedman, Margaret Gatti-Mays, Meliss...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• 4 citations
  DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
  Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton, Camille Gunderson Jackson, Kristopher LyBarger, Howard M Goodman, Linda R Duska, Haider...> ;Gynecologic Oncology. 2023 May 1
• 7 citations
  Immunotherapy in endometrial cancer.
  Haider Mahdi, Anca Chelariu-Raicu, Brian M Slomovitz> ;International Journal of Gynecological Cancer. 2023 Mar 6
• 2 citations
  The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
  T J Orellana, A A Garrett, T R Soong, T Rives, M Courtney-Brooks, S E Taylor, J Lesnock, J Berger, M Boisen, L Coffman, R Buckanovich, H Mahdi, J C Comerci, S Beriwal,...> ;Gynecologic Oncology. 2023 Mar 1
• Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
  Mary Woodall-Jappe, Preeti Singh, Myron S Czuczman, Haider S Mahdi> ;Frontiers in Immunology. 2023 Jan 1
• Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.
  Paul G Pavicic Jr, Patricia A Rayman, Shadi Swaidani, Amit Rupani, Vladimir Makarov, Charles S Tannenbaum, Robert P Edwards, Anda M Vlad, C Marcela Diaz-Montero, Haide...> ;Oncoimmunology. 2023 Jan 1
• 1 citations
  Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer.
  Alison A Garrett, Alyssa Wield, Brigid Mumford, Isabel Janmey, Li Wang, Philip Grosse, Emily MacArthur, Ronald Buckanovich, Madeleine Courtney-Brooks, Paniti Sukumvani...> ;Gynecologic Oncology Reports. 2022 Dec 1
• 2 citations
  Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
  Sarah A Ackroyd, David Arguello, Pilar Ramos, Haider Mahdi, Adam ElNaggar, Ira Winer, Rob Holloway, Thomas Krivak, Nathaniel Jones, Valerie Galvan Turner, Thomas Herzo...> ;Gynecologic Oncology. 2023 Feb 1
• 6 citations
  Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
  Lan G Coffman, Taylor J Orellana, Tianshi Liu, Leonard G Frisbie, Daniel Normolle, Kent Griffith, Shitanshu Uppal, Karen McLean, Jessica Berger, Michelle Boisen, Madel...> ;JCI Insight. 2022 Sep 22
• 22 citations
  Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors.
  Xiangxue Wang, Cristian Barrera, Kaustav Bera, Vidya Sankar Viswanathan, Sepideh Azarianpour-Esfahani, Can Koyuncu, Priya Velu, Michael D Feldman, Michael Yang, Pingfu...> ;Science Advances. 2022 Jun 3
• Prophylactic Salpingo-Opphorectomy in Patients With Hereditary Predisposition Genes for Ovarian Cancer.
  Alison A Garrett, Haider Mahdi> ;JCO Oncology Practice. 2022 Jun 1
• 11 citations
  Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and...
  Brian Orr, Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana, Lixin Zhang, Adria Suarez Mora, Alexandra Pusateri, Esther Elishaev, Chaeryon Kang, Geor...> ;Clinical Cancer Research. 2022 May 13
• Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer.
  Anca Chelariu-Raicu, Haider Mahdi, Brian M Slomovitz> ;Current Opinion in Obstetrics & Gynecology. 2022 Feb 1
• 9 citations
  Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities.
  Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Patrick Leo, Pingfu Fu, Paula Toro, Amy Joehlin-Price, Mojgan Mokhtari, Haider Mahdi, Anant Madabhushi> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
• 26 citations
  High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.
  Ying Ni, Ahmed Soliman, Amy Joehlin-Price, Peter G Rose, Anda Vlad, Robert P Edwards, Haider Mahdi> ;NPJ Precision Oncology. 2021 Dec 17
• 31 citations
  Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition
  Sandra Cascio, Chelsea Chandler, Linan Zhang, Sarah Sinno, Bingsi Gao, Sayali Onkar, Tullia C. Bruno, Dario A. A. Vignali, Haider Mahdi, Hatice U. Osmanbeyoglu, Anda M...> ;Science Advances. 2021 Nov 12
• 7 citations
  Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
  Taylor Orellana, Hyun Soo Kim, Sushil Beriwal, Rohit Bhargava, Jessica Berger, Ronald J. Buckanovich, Lan G. Coffman, Madeleine Courtney-Brooks, H. Mahdi, Alexander B....> ;Gynecologic Oncology. 2021 Nov 2
• 6 citations
  PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
  Peter G. Rose, Meng Yao, Laura M. Chambers, Haider Mahdi, Robert Debernardo, Chad M. Michener, Miriam AlHilli, Stephanie Ricci, Roberto Vargas> ;Anti-Cancer Drugs. 2021 Nov 1
• 32 citations
  Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
  Haider Mahdi, Navid Hafez, Deborah Blythe Doroshow, Davendra Sohal, Vickie L. Keedy, Khanh T. Do, Patricia LoRusso, Juliane Jürgensmeier, Manuel Avedissian, Jeffrey Sk...> ;JCO Precision Oncology. 2021 Sep 7
• Join now to see all

Lectures

• The role of different TGFβ signatures in predicting outcome in high grade serous ovarian carcinoma. 
  2019 ASCO Annual Meeting - 6/1/2019
• The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma. 
  2019 ASCO Annual Meeting - 6/1/2019